Outcomes of Open Radical Nephrectomy for Advanced Renal Malignant Tumors in the Minimally Invasive Era: Findings From

Mahmoud Mohammed1,2, Hesham M Hamza3, Ali Zedan3

  • 1Surgical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, EGY.

Cureus
|September 15, 2025
PubMed

Insights

Open radical nephrectomy (ORN) remains crucial for large, complex renal tumors, offering superior control despite advances in minimally invasive surgery (MIS). Maintaining open surgical skills is vital for urologic oncology practices to ensure optimal oncologic outcomes.

Area of Science:

  • Urology
  • Surgical Oncology
  • Nephrology

Background:

  • Minimally invasive surgery (laparoscopic, robotic) is increasingly used for renal tumors.
  • Open surgery is still performed for large or complex tumors with nodal or vascular invasion.
  • This study reviews elective open radical nephrectomy (ORN) for high-risk cases.

Purpose of the Study:

  • To evaluate the institutional experience with elective open radical nephrectomy (ORN) over 17 years.
  • To assess oncologic outcomes and perioperative safety in patients with challenging renal tumors undergoing ORN.

Main Methods:

  • Retrospective review of 105 patients undergoing ORN (January 2007-June 2024).
  • Data included tumor characteristics, nodal status, vascular invasion, perioperative outcomes, and survival.
  • Analysis included Kaplan-Meier for disease-specific survival (DSS) and overall survival (OS).

Main Results:

  • Median tumor size was 10.7 cm; 66% were ≥10 cm.
  • Locally advanced disease (T3-T4) was common; 20% had IVC thrombus, 45% renal vein thrombus.
  • 40% had clinically positive lymph nodes; 4% experienced major complications (Clavien-Dindo ≥III).

Conclusions:

  • Open radical nephrectomy (ORN) is essential for large, node-positive, or vascular-invasive renal tumors.
  • ORN provides critical advantages in exposure, vascular control, and complete resection compared to MIS.
  • Surgical expertise in open techniques must be preserved in urologic oncology.